TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02807623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compound Exercise of Push-ups
Description: The participants will perform an exercise intervention of push-ups as immediately as possible but no more than 15 minutes after influenza vaccine receipt. The number of pushups performed will be at least 80% of the participants last Army Physical Fitness Test (APFT) score in one session. The number of pushups will be recorded. A baseline lactate fingerstick blood specimen will be collected with either the serology sample (if possible) or from the hand opposite the vaccine receipt arm prior to performing pushups and a second finger stick sample within 3-8 minutes, but no more than 15 minutes after vaccine receipt.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo
Description: The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
Study: NCT04081922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Using ultrasound, place the needle in the erector spinae fascia plane at T7-8 level. Then, 0.25% ropivacaine 0.5 ml is injected to confirm the needle location. After checking the location, 0.25% ropivacaine 0.5 ml/kg is administered. This procedure is repeated at contralateral side.
Study: NCT03190395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI Group
Description: CPVI Group:The ablation strategy of Circumferential pulmonary vein isolation (CPVI)will be operated on 60 patients with paroxysmal atrial fibrillation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPVI+LARA Group
Description: CPVI+LARA Group: The ablation strategy of Circumferential pulmonary vein isolation combine with Left atrium roofline ablation(CPVI+LARA) will be operated on 60 patients with paroxysmal atrial fibrillation.
Study: NCT03840863

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Commercially-Available Energy Drink
Description: Participant will consume 2 cans of an energy drink (16 oz./can) per day. One in the morning and one in the afternoon.
Study: NCT02498301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin will be provided to subjects either daily with placebo, or twice daily depending on which of the two experimental arms they are randomized to

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin will be provided to subjects either daily with placebo, or twice daily depending on which of the two experimental arms they are randomized to
Study: NCT00660543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DSC MRI
Study: NCT02498301

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to
Study: NCT00908453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosphenytoin
Description: 15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosphenytoin
Description: 15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
Study: NCT00660543

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DSC MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DSC MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging
Description: Undergo DWI
Study: NCT00908453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosphenytoin
Description: 15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
Study: NCT05229484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: an integrated multimodal lifestyle intervention (MLifeI)
Description: The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.
Study: NCT00930891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy (PCDE or PE)
Description: PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Treatment (PCDE or PE + bevacizumab)
Description: PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prerandomization Chemotherapy (PCDE or PE)
Description: PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles~PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prerandomization Chemotherapy (PCDE or PE)
Description: PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles~PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles
Study: NCT02933788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol sustained release capsule is new drugs developed by Otsuka Korea. This drugs have platelet aggregation inhibiting action, peripheral vasodilating action and endothelial function improving action.
Study: NCT00660543

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diffusion Weighted Imaging
Description: Undergo DWI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diffusion Weighted Imaging
Description: Undergo DWI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI-Based Angiogram
Description: Undergo TOF MR angiography
Study: NCT02933788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Aspirin may prevent coronary thrombosis in patients with cardiovascular event risk factors, such as ischemic heart disease family history, hypertension, diabetes mellitus, dyslipidemia and obesity.
Study: NCT03921827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhance External Counterpulsation Therapy
Description: EECP therapy would be administered to this group for 1-hour a day for a total of 35 sessions
Study: NCT01775644

Intervention type: DRUG
Intervention: Bevacizumab
Description: Administration of treatment will be as used in normal daily routine under local labeling.
Study: NCT02219646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil
Description: Vardenafil 10 mg twice daily for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo two tablets daily for 6 months
Study: NCT02752880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH1 group
Description: Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
Study: NCT00515151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Octenidine with 30% 1-propanol and 45% 2-propanol
Description: Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of \>200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 74% Ethanol with 10% 2-propanol
Description: Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of \>200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
Study: NCT00660543

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI-Based Angiogram
Description: Undergo TOF MR angiography

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI-Based Angiogram
Description: Undergo TOF MR angiography
Study: NCT01680484

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bitter chocolate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice
Study: NCT02253901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BILR 355 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Study: NCT01248195

Intervention type: DRUG
Group type: OTHER
Intervention: Amisulpride open label
Description: 4-week open label amisulpride treatment
Study: NCT02253901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study: NCT01248195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-week amisulpride double blind treatment
Description: 6-week amisulpride double blind treatment
Study: NCT02253901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRUVADA
Study: NCT01198756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal influenza vaccine GSK2282512A
Description: For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 17 years of age, single intramuscular dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™ VB
Description: For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™ YB
Description: For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose
Study: NCT01248195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-week olanzapine double blind treatment
Description: 6-week olanzapine double blind treatment

Intervention type: DRUG
Group type: OTHER
Intervention: 12-week clozapine open-label treatment
Description: 12-week clozapine open-label treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: Psychosocial intervention
Study: NCT00506350

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose
Description: A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose
Description: A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose
Description: A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
Study: NCT01198756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal influenza vaccine GSK2282512A
Description: Single intramuscular dose for primed subjects, two doses for unprimed subjects.
Study: NCT01127893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
Study: NCT00506350

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose
Description: A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses
Description: Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses
Description: Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses
Description: Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses
Description: Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.
Study: NCT01127893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
Study: NCT00506350

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses
Description: Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.
Study: NCT04154436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (NaHCO3) Plus Solution
Description: Alkaline Solution
Study: NCT03723616

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will view 24 ads with and without health warnings. Additionally, 16 control non-tobacco ads matched for graphical content, presence of text, people, and other factors will be randomly distributed among these ads.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will view 24 ads with and without health warnings. Additionally, 16 control non-tobacco ads matched for graphical content, presence of text, people, and other factors will be randomly distributed among these ads.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Only
Description: Participants will view at random 24 ads twice, each ad will have a different health warning chosen at random with the caveat that each health warning will be seen 3 times. The 16 control ads will have text disclaimers to control for physical features of the ads.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Only
Description: Participants will view at random 24 ads twice, each ad will have a different health warning chosen at random with the caveat that each health warning will be seen 3 times. The 16 control ads will have text disclaimers to control for physical features of the ads.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text + Graphic
Description: This arm is identical to the text only intervention except a graphic will be added to the health warning. Thus, each ad will be seen twice; the text + graphic warnings will be seen three times. The 16 control ads will have text disclaimers and logos or other images to control for physical features of ads.
Study: NCT04154436

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water (H2o)
Description: Alkaline Solution
Study: NCT03723616

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text + Graphic
Description: This arm is identical to the text only intervention except a graphic will be added to the health warning. Thus, each ad will be seen twice; the text + graphic warnings will be seen three times. The 16 control ads will have text disclaimers and logos or other images to control for physical features of ads.
Study: NCT03339700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 4800mg/m2, intravenous (IV), divided 4 days, 1200mg/m2/day, during days -5 to -2
Study: NCT03910504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0.3 mg*kg
Description: Patients randomized to the control group will receive rocuronium at 0.3 mg\*kg ev bolus at the induction of anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No Rocuronium
Description: Patients randomized to the interventional group will not receive neuromuscular blockade at the induction of anesthesia.
Study: NCT01906333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasted
Study: NCT04325971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuroimaging
Description: MR, EEG recordings
Study: NCT03339700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7 to -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 80mg/kg, intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 and -2.
Study: NCT04458506

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary expansion
Description: Correction of the unilateral posterior cross bite in children
Study: NCT03339700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
Study: NCT04458506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary expansion
Description: Correction of the unilateral posterior cross bite in children
Study: NCT01733173

Intervention type: PROCEDURE
Intervention: MRI with DTI and fMRI
Description: When possible, the subject will undergo a post operative fMRI/ DTI scan as well as clinical language testing. If the subject develops CMS, the second fMRI will be performed as soon as possible. Some subjects may be severely impaired or have difficulty performing fMRI and clinical language testing tasks. In these instances, the fMRI and language testing may not be performed, or we may choose to perform resting state or passive fMRI tasks instead.
Study: NCT05351684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 MG
Description: already included in arm/group descriptions.
Study: NCT00997035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing \<40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment.
Study: NCT03694405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: Booster vaccination with MenACWY-CRM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: Booster vaccination with MenACWY-CRM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: Booster vaccination with MenACWY-CRM
Study: NCT00689585

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250mg matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Description: 500-1500mg/day over a 1-5 week dose titration period until maximal tolerated dose (MTD) attained, followed by 1 week MTD plateau period.
Study: NCT00189488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Administered as an intravenous (IV) bolus.
Study: NCT03694405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-DT
Description: Booster vaccination with MenACWY-DT